{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:11:43Z","timestamp":1790820703089,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are potentially fatal cutaneous adverse events of drug treatment. Evidence for SJS\/TEN risk from current anticancer therapies in population-based studies is scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The present study aims to characterize the profiles and risk factors of SJS\/TEN related to contemporary anticancer regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Reported odds ratios (ROR) were employed to identify anticancer drugs associated with SJS\/TEN development using FAERS data from January 2004 to September 2024. Single factor, LASSO, and multivariable logistic regression analysis were performed to explore the risk factors of SJS\/TEN related to anticancer therapies. Weibull shape parameter analysis was applied to the onset time of reported SJS\/TEN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3471 unique SJS\/TEN events were identified for 159 anticancer drug pairs, of which 31 drugs were identified as significantly disproportionate. Targeted therapies accounted for 35.93% of pairs, chemotherapies for 35.52%, and immunotherapies for 21.52%. The median onset time of SJS\/TEN with anticancer therapies was 17 days. Moreover, multivariable logistic regression showed that age exceeding 65, female gender, and 10 anticancer drugs were significant risk factors for anticancer therapy-related SJS\/TEN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides real-world evidence regarding the burden of SJS\/TEN associated with anticancer therapies. Addressing this knowledge gap will facilitate the optimization of clinical management for SJS\/TEN. Further research to establish causality and inform clinical decision-making related to anticancer therapy-associated SJS\/TEN is urgently needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1646038","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T05:18:43Z","timestamp":1756271923000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Emerging causes of anticancer therapies\u2212induced Stevens-Johnson syndrome and toxic epidermal necrolysis: evidence from disproportionality analysis of the FDA adverse event reporting system"],"prefix":"10.3389","volume":"16","author":[{"given":"Wensheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-024-00889-6","article-title":"Update on Stevens-Johnson syndrome and toxic epidermal necrolysis: diagnosis and management","volume":"25","author":"Shah","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/bjd\/ljae321","article-title":"Recent progress in Stevens-Johnson syndrome\/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment","volume":"192","author":"Hama","year":"2024","journal-title":"Br J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.3575","article-title":"Incidence, in-hospital and long-term mortality, and sequelae of epidermal necrolysis in adults","volume":"160","author":"Bettuzzi","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2019.0977","article-title":"Toxic epidermal necrolysis and steven-johnson syndrome: A comprehensive review","volume":"9","author":"Charlton","year":"2020","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165933","article-title":"Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: A nationwide population-based study using national health insurance database in Korea","volume":"11","author":"Yang","year":"2016","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08859-0","article-title":"Current perspectives on severe drug eruption","volume":"61","author":"Zhang","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14591","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System","volume":"59","author":"Borrelli","year":"2018","journal-title":"Epilepsia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.6378","article-title":"Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.896867","article-title":"Stevens-johnson syndrome following non-steroidal anti-inflammatory drugs: A real-world analysis of post-marketing surveillance data","volume":"10","author":"Shao","year":"2022","journal-title":"Front Pediatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211027945","article-title":"Capecitabine induced Steven-Johnson syndrome: A rare case report","volume":"28","author":"Karthikeyan","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47457","article-title":"A diagnostic quandary: carboplatin-paclitaxel-induced Stevens-Johnson syndrome in a rare case of carcinosarcoma of the esophagus and review of the literature","volume":"15","author":"Gokulanathan","year":"2023","journal-title":"Cureus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1456","article-title":"Evaluation of anticancer therapy-related dermatologic adverse events: Insights from Food and Drug Administration\u2019s Adverse Event Reporting System dataset","volume":"91","author":"Salah","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S454673","article-title":"Emerging insights into Stevens-Johnson syndrome and toxic epidermal necrolysis induced by immune checkpoint inhibitor and tumor-targeted therapy","volume":"17","author":"Lin","year":"2024","journal-title":"J Inflammation Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaip.2024.10.027","article-title":"Class I HLA alleles are associated with an increased risk of osimertinib-induced hypersensitivity","volume":"13","author":"Chen","year":"2025","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S491791","article-title":"Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis induced by immune checkpoint inhibitor versus non-immune checkpoint inhibitor drugs in China: A cross-sectional study and literature review","volume":"17","author":"Qin","year":"2024","journal-title":"J Inflammation Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/cup.14687","article-title":"Toxic epidermal necrolysis-like cutaneous toxicity following chimeric antigen receptor T-cell therapy in recurrent large B-cell lymphoma","volume":"51","author":"Bhullar","year":"2024","journal-title":"J Cutan Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for drUg safety signal detection using individual case safety reports in pharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1558128","article-title":"Emerging cardiovascular toxicity associated with CDK4\/6 inhibitors: real-world insights from the FDA adverse event reporting system","volume":"16","author":"Liu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy","volume":"26","author":"Sibaud","year":"2016","journal-title":"Eur J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2015.01.002","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: the Food and Drug Administration adverse event reporting system, 2004-2013","volume":"64","author":"Abe","year":"2015","journal-title":"Allergol Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jdin.2022.12.002","article-title":"Risk factors and drugs that trigger the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis: A population-based cohort study using the Shizuoka Kokuho database","volume":"11","author":"Ubukata","year":"2022","journal-title":"JAAD Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/jnr.10766","article-title":"Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity","volume":"74","author":"Tsaknaridis","year":"2003","journal-title":"J Neurosci Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0511","article-title":"Anticancer agent-induced life-threatening skin toxicities: A database study of spontaneous reporting data","volume":"24","author":"Tanaka","year":"2019","journal-title":"Oncologist"},{"key":"B27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40780-016-0048-5","article-title":"Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database","volume":"2","author":"Abe","year":"2016","journal-title":"J Pharm Health Care Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jaci.2022.12.005","article-title":"Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions","volume":"151","author":"Gibson","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3186328","article-title":"HLA association with drug-induced adverse reactions","volume":"2017","author":"Fan","year":"2017","journal-title":"J Immunol Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.02.003","article-title":"SJS\/TEN 2019: From science to translation","volume":"98","author":"Chang","year":"2020","journal-title":"J Dermatol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5376476","article-title":"Anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies","volume":"2018","author":"Ng","year":"2018","journal-title":"J Immunol Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.05.018","article-title":"Toxic erythema of chemotherapy: a useful clinical term","volume":"59","author":"Bolognia","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14010","article-title":"Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure","volume":"31","author":"Arenbergerova","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.027","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis reactions to BRAF and MEK inhibitors in patients with melanoma: A systematic review","volume":"85","author":"Lytvyn","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/CJI.0000000000000302","article-title":"Combination therapy of ipilimumab and nivolumab-associated toxic epidermal necrolysis (TEN) in a patient with metastatic melanoma: A case report and literature review","volume":"43","author":"Logan","year":"2020","journal-title":"J Immunother"},{"key":"B39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s10637-024-01499-z","article-title":"Clinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"43","author":"Wu","year":"2025","journal-title":"Invest New Drugs"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1346-8138.17039","article-title":"Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications","volume":"51","author":"Satoh","year":"2024","journal-title":"J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1297420","article-title":"Meta-analysis of randomized controlled\u00a0trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab","volume":"16","author":"Zhu","year":"2017","journal-title":"Expert Opin Drug Saf"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1646038\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T05:18:45Z","timestamp":1756271925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1646038\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2025.1646038"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1646038","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"article-number":"1646038"}}